|
Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060 EISSN: 1678-8060
Vol. 92, No. s2, 1997, pp. 69-73
|
Bioline Code: oc97171
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Memórias do Instituto Oswaldo Cruz, Vol. 92, No. s2, 1997, pp. 69-73
en |
Pulmonary Biology Of Anti-interleukin 5 Antibodies
Egan, R.W.; Athwahl, D.; Chou, C-C.; Chapman, R.W.; Emtage, S.; Jenh, C-H.; Kung, T.T.; Mauser, P.J.; Murgolo, N.J. & Bodmer, M.W.
Abstract
Interleukin 5 (IL-5) is a critical cytokine for the maturation of
eosinophil precursors to eosinophils in the bone marrow and those
eosinophils then accumulate in the lungs during asthma. We have studied
anti IL-5 antibodies on allergic responses in mice, guinea pigs and monkeys
and are extending this experiment into humans with a humanized antibody. In
a monkey model of pulmonary inflammation and airway hyperreactivity, we
found that the TRFK-5 antibody blocked both responses for three months
following a single dose of 0.3 mg/kg, i.v. This antibody also blocked lung
eosinophilia in mice by inhibiting release from the bone marrow. To
facilitate multiple dosing and to reduce immunogenicity in humans, we
prepared Sch 55700, a humanized antibody against IL-5. Sch 55700 was also
active against lung eosinophilia in allergic monkeys and mice and against
pulmonary eosinophilia and airway hyperresponsiveness in guinea pigs.
Furthermore, as opposed to steroids, Sch 55700 did not cause
immunosuppression in guinea pigs. Studies with this antibody in humans will
be critical to establishing the therapeutic potential of IL-5 inhibition.
Keywords
eosinophils - interleukin-5 - pulmonary inflammation - antibodies - airway hyperresponsiveness
|
|
© Copyright 1997 Fundacao Oswaldo Cruz - Fiocruz Alternative site location: http://memorias.ioc.fiocruz.br
|
|